Fewer COVID-19 Neurological Complications with Dexamethasone and Remdesivir.

Alexander GrundmannChieh-Hsi WuMarc HardwickJ Kenneth BailliePeter J M OpenshawMalcolm G SempleDankmar BöhningSarah PettBenedict D MichaelRhys H ThomasIan Galeanull null

Published in: Annals of neurology (2022)

Treatment with dexamethasone, remdesivir, or both in patients hospitalized with COVID-19 was associated with a lower frequency of neurological complications in an additive manner, such that the greatest benefit was observed in patients who received both drugs together. ANN NEUROL 2022.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
low dose
ejection fraction
high dose
risk factors
chronic kidney disease
peritoneal dialysis
prognostic factors
respiratory syndrome coronavirus
patient reported outcomes
neural network